<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="../../util/style/eu-regional.xsl"?>
<!DOCTYPE eu:eu-backbone SYSTEM "../../util/dtd/eu-regional.dtd">
<eu:eu-backbone xmlns:eu="http://europa.eu.int" xmlns:xlink="http://www.w3c.org/1999/xlink" xml:lang="en" dtd-version="1.4">
	<eu-envelope>
		<envelope country='emea'>
			<submission type='supplemental-info'>
				<tracking>
					<number>EMEA/H/C/002392//0000</number>
				</tracking>
			</submission>
			<applicant>Bayer</applicant>
			<agency code='EU-EMEA'/>
			<procedure type='centralised' />
			<invented-name>Eylea</invented-name>
			<inn>Aflibercept</inn>
			<sequence>0001</sequence>
			<related-sequence>0000</related-sequence>
			<submission-description>Validation Response June 2011</submission-description>
		</envelope>
	</eu-envelope>
	<m1-eu>
		<m1-0-cover>
			<specific country="emea">
				<leaf ID="NBSI5696EC5F01CC2C17" operation="new" xlink:href="10-cover/emea/emea-cover-2.pdf" checksum-type="md5" checksum="51414e7bd880d345905e520d876f1c84">
					<title>1.0.1.1-emea Cover Letter 0001</title>
				</leaf>
			</specific>
		</m1-0-cover>
		<m1-2-form>
			<specific country="emea">
				<leaf ID="NBSIF0D89D1901CC1C67" operation="replace" xlink:href="12-form/emea/emea-form.pdf" modified-file="../../../0000/m1/eu/eu-regional.xml#NBSI0566288601CBFE94" checksum-type="md5" checksum="d1e091b3c6283f5372f9e5824b9699b5">
					<title>1.2.1 Application Form - 0001</title>
				</leaf>
				<leaf ID="NBSIF5C1187D01CC1C67" operation="replace" xlink:href="12-form/emea/emea-form-annex512.pdf" modified-file="../../../0000/m1/eu/eu-regional.xml#NBSI0B0D5BEC01CBFE94" checksum-type="md5" checksum="cc9db3839d550b016e693134a79421ce">
					<title>1.2.1 Annex 5.12 Ph. Eur. Certificate(s) of Suitability for TSE 0001</title>
				</leaf>
			</specific>
		</m1-2-form>
		<m1-3-pi>
			<m1-3-1-spc-label-pl>
				<pi-doc xml:lang="en" type="combined" country="emea">
					<leaf ID="NBSIF9FDEA0101CC1C67" operation="replace" xlink:href="13-pi/131-spclabelpl/emea/en/emea-combined-h2392en.pdf" modified-file="../../../0000/m1/eu/eu-regional.xml#NBSI0EB1936201CBFE94" checksum-type="md5" checksum="3206820afc388ae336e8d99feec043cc">
						<title>1.3.1.8c-emea-en-combined emea-combined-h2392en</title>
					</leaf>
				</pi-doc>
			</m1-3-1-spc-label-pl>
			<m1-3-6-braille>
				<leaf ID="NBSIFFE0BD2101CC1C67" operation="new" xlink:href="13-pi/136-braille/braille.pdf" checksum-type="md5" checksum="ec077dda464a7876594d3db4a23552f0">
					<title>1.3.6 Justification Braille 0001</title>
				</leaf>
			</m1-3-6-braille>
		</m1-3-pi>
		<m1-8-pharmacovigilance>
			<m1-8-1-pharmacovigilance-system>
				<leaf ID="NBSI02D4890D01CC1C68" operation="replace" xlink:href="18-pharmacovigilance/181-phvig-system/phvigsystem.pdf" modified-file="../../../0000/m1/eu/eu-regional.xml#NBSI1B35EBE201CBFE94" checksum-type="md5" checksum="9b8a9d7de86aaa552bda27be1fdbca2d">
					<title>1.8.1.1 Pharmacovigilance System 0001</title>
				</leaf>
			</m1-8-1-pharmacovigilance-system>
			<m1-8-2-risk-management-system>
				<leaf ID="NBSI04CDFD3D01CC1C68" operation="replace" xlink:href="18-pharmacovigilance/182-riskmgt-system/riskmgtsystem.pdf" modified-file="../../../0000/m1/eu/eu-regional.xml#NBSI1F79E0E601CBFE94" checksum-type="md5" checksum="a078dd774dc6c5336d4264b5ef7029ae">
					<title>1.8.2.1 Risk-management System 0001</title>
				</leaf>
			</m1-8-2-risk-management-system>
		</m1-8-pharmacovigilance>
		<m1-9-clinical-trials>
			<leaf ID="NBSIC1B4286001CC2CD3" operation="new" xlink:href="19-clinical-trials/clinicaltrials-2.pdf" checksum-type="md5" checksum="8b21dfc92f4b42f9fefa5e3c966aabd0">
				<title>1.9.2 Bayer list of studies and involved countries 0001</title>
			</leaf>
			<leaf ID="NBSIC1C2765201CC2CD3" operation="new" xlink:href="19-clinical-trials/clinicaltrials-3.pdf" checksum-type="md5" checksum="9efc9657e3efc5c6405a33997f96dd5c">
				<title>1.9.3 Regeneron GCP statement and list of trials 0001</title>
			</leaf>
			<leaf ID="NBSIEEB0105501CC2CF0" operation="new" xlink:href="19-clinical-trials/clinicaltrials-4.pdf" checksum-type="md5" checksum="0a2b269729fa7186ac008a4b025ef68c">
				<title>1.9.4 VIEW 1 CSR Signature of Coordinating Investigator 0001</title>
			</leaf>
			<leaf ID="NBSIEEB735FB01CC2CF0" operation="new" xlink:href="19-clinical-trials/clinicaltrials-5.pdf" checksum-type="md5" checksum="0068b2e4a188e9c44e2f9fdf4e896011">
				<title>1.9.5 VIEW 2 CSR Signature of Coordinating Investigator 0001</title>
			</leaf>
		</m1-9-clinical-trials>
		<m1-10-paediatrics>
			<leaf ID="NBSI046B83A401CC2C1F" operation="new" xlink:href="110-paediatrics/paediatrics-2.pdf" checksum-type="md5" checksum="ac6173fb79daaded02e17c451eb43064">
				<title>1.10.2 European Medicines Agency PIP decision on class waivers 0001</title>
			</leaf>
		</m1-10-paediatrics>
	</m1-eu>
</eu:eu-backbone>
